Clinical Outcomes and Response to Vericiguat According to Index Heart Failure Event: Insights From the VICTORIA Trial.

ABSTRACT:

Importance

The period following heart failure hospitalization (HFH) is a vulnerable time with high rates of death or recurrent HFH.

Objective

To evaluate clinical characteristics, outcomes, and treatment response to vericiguat according to prespecified index event subgroups and time from index HFH in the Vericiguat Global Study in Subjects With Heart Failure With Reduced Ejection Fraction (VICTORIA) trial.

Design, setting, and participants

Analysis of an international, randomized, placebo-controlled trial. All VICTORIA patients had recent (<6 months) worsening HF (ejection fraction <45%). Index event subgroups were less than 3 months after HFH (n = 3378), 3 to 6 months after HFH (n = 871), and those requiring outpatient intravenous diuretic therapy only for worsening

SUBMITTER: Lam CSP 

PROVIDER: S-EPMC7666431 | biostudies-literature | 2021 Jun

REPOSITORIES: biostudies-literature